Evidence map›Paper›PMID 42410650›Full record

ArticleChinese medicine2026

Shengxian decoction suppresses malignant progression of lung adenocarcinoma by enhancing CD8

Qiong Ma, Xiao Zeng, Chunxia Huang, Xingyue Liu, Jiawei He, Yuting Bai, Yuxuan Xiong, Shiyan Tan, Zongyi Mao, Xueke Li and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chinese medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Qiong Ma *Hospital of Chengdu University of Traditional Chinese Medicine, No.39, Shierqiao Road, Jinniu District, Chengdu, 610075, China.
Xiao Zeng *Hospital of Chengdu University of Traditional Chinese Medicine, No.39, Shierqiao Road, Jinniu District, Chengdu, 610075, China.
Chunxia Huang *Hospital of Chengdu University of Traditional Chinese Medicine, No.39, Shierqiao Road, Jinniu District, Chengdu, 610075, China.
Xingyue LiuHospital of Chengdu University of Traditional Chinese Medicine, No.39, Shierqiao Road, Jinniu District, Chengdu, 610075, China.
Jiawei HeHospital of Chengdu University of Traditional Chinese Medicine, No.39, Shierqiao Road, Jinniu District, Chengdu, 610075, China.
Yuting BaiHospital of Chengdu University of Traditional Chinese Medicine, No.39, Shierqiao Road, Jinniu District, Chengdu, 610075, China.
Yuxuan XiongHospital of Chengdu University of Traditional Chinese Medicine, No.39, Shierqiao Road, Jinniu District, Chengdu, 610075, China.
Shiyan TanHospital of Chengdu University of Traditional Chinese Medicine, No.39, Shierqiao Road, Jinniu District, Chengdu, 610075, China.
Zongyi MaoHospital of Chengdu University of Traditional Chinese Medicine, No.39, Shierqiao Road, Jinniu District, Chengdu, 610075, China.
Xueke LiHospital of Chengdu University of Traditional Chinese Medicine, No.39, Shierqiao Road, Jinniu District, Chengdu, 610075, China.
Qian WangHospital of Chengdu University of Traditional Chinese Medicine, No.39, Shierqiao Road, Jinniu District, Chengdu, 610075, China.
Xi FuHospital of Chengdu University of Traditional Chinese Medicine, No.39, Shierqiao Road, Jinniu District, Chengdu, 610075, China. fuxi884853@163.com.
Fengming YouHospital of Chengdu University of Traditional Chinese Medicine, No.39, Shierqiao Road, Jinniu District, Chengdu, 610075, China. yfmdoc@163.com.
Yifeng RenHospital of Chengdu University of Traditional Chinese Medicine, No.39, Shierqiao Road, Jinniu District, Chengdu, 610075, China. ryftcm.dr@yahoo.com.
Chuan ZhengHospital of Chengdu University of Traditional Chinese Medicine, No.39, Shierqiao Road, Jinniu District, Chengdu, 610075, China. zhengchuan@cdutcm.edu.cn.

Funding

China Postdoctoral Science Foundation, China 2025T181079Postdoctoral Fellowship Program and China Postdoctoral Science Foundation,China BX20250214Sichuan Science and Technology Program, China 2025ZNSFSC1850
6 · The paper itself

Abstract

backgroundShengxian Decoction (SXD), a traditional Chinese herbal formula, has demonstrated significant clinical efficacy against lung adenocarcinoma (LUAD). However, its exact mechanisms of action remain to be elucidated. This study aimed to establish an animal model capable of simulating the dynamic progression of LUAD to investigate the anti-tumor effects and immunomodulatory mechanisms of SXD.

methodsA TK (Trp53

resultsAn immunocompetent TK-LUAD mouse model was successfully established, showing the dynamic pathological progression of LUAD and accompanying changes in immune infiltration. SXD treatment significantly delayed malignant progression in this model and was associated with modulation of the tumor immune microenvironment, as reflected by increased CD8

conclusionThis study establishes an immunocompetent animal model for investigating LUAD progression and associated changes in the tumor immune microenvironment. In addition, this study provides evidence suggesting that the antitumor activity of SXD may be associated with FYN-related activation of the PI3K/AKT signaling pathway and subsequent enhancement of CD8

Indexed as

CRISPR/Cas9FYN-PI3K/AKT axisLung adenocarcinomaOrganoidShengxian Decoction (SXD)

Identifiers

PMID42410650
PMCPMC13335393

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.